Lilly drug chosen for Alzheimer’s prevention study

Published



Researchers have chosen an experimental drug by Eli Lilly & Co. for a large federally funded study testing whether it’s possible to prevent Alzheimer’s disease in older people at high risk of developing it.

The drug, called solanezumab (sol-ah-NAYZ-uh-mab), is designed to bind to and help clear the sticky deposits that clog patients’ brains.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.